Granted Patent B2

US 12,534,764 · App. 17/234,250 · Granted Jan 27, 2026

Inventor: Vinay K. Jain (Dallas, TX)

Assignee: Arog Pharmaceuticals, Inc.

C12Q1/6886C12Q2600/106C12Q2600/118C12Q2600/156

Abstract

Claims (33)

1 . A method for treating a human leukemia patient with crenolanib, where the leukemia is characterized by one or more deregulated FLT3 receptors, or one or more constitutively active FLT3 receptors, and one or more driver mutations in a NPM1 nuclear transport protein, the method comprising:

first, obtaining a biological sample from a human patient's leukemia;

then, assaying the sample for expression of one or more deregulated FLT3 receptors, one or more constitutively active FLT3 receptors, and the presence of one or more mutations in a NPM1 nuclear transport protein;

then, determining that the patient has a poor prognosis for leukemia based on the detection of the deregulated FLT3 receptor or the constitutively active FLT3 receptor, and the presence of one or more driver mutations in the NPM1 nuclear transport protein;

then administering to the human patient a therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof, thereby treating the leukemia which has both the deregulated FLT3 receptor or the constitutively active FLT3 receptor and one or more driver mutations in the NPM1 nuclear transport protein.

2 . The method of claim 1 , wherein the FLT3 mutation is selected from at least one of FLT3-ITD or FLT3-TKD.

3 . The method of claim 1 , wherein the therapeutically effective amount of crenolanib or the pharmaceutically acceptable salt thereof are from about 50 to 500 mg per day, 100 to 450 mg per day, 200 to 400 mg per day, 300 to 500 mg per day, 350 to 500 mg per day, or 400 to 500 mg per day; or

the therapeutically effective amount of crenolanib or the pharmaceutically acceptable salt thereof is administered at least one of continuously, intermittently, systemically, or locally; or

the therapeutically effective amount of crenolanib or the pharmaceutically acceptable salt thereof is administered orally, intravenously, or intraperitoneally.

4 . The method of claim 1 , wherein the crenolanib or the pharmaceutically acceptable salt thereof is crenolanib besylate, crenolanib phosphate, crenolanib lactate, crenolanib hydrochloride, crenolanib citrate, crenolanib acetate, crenolanib toluenesulphonate, and crenolanib succinate.

5 . The method of claim 1 , wherein the method comprises of at least one of:

administering up to three times or more a day for as long as the human patient is in need of treatment for the leukemia; or

providing at least one of sequentially or concomitantly, with another pharmaceutical agent, to maintain remission of an existing human leukemia patient, or in a relapsed/refractory human leukemia patient; or

providing as a single agent or in combination with another pharmaceutical agent to maintain remission, or in a relapse/refractory human leukemia patient; or

providing as a single agent or in combination with another pharmaceutical agent to maintain remission, or in a relapsed/refractory human pediatric leukemia patient.

6 . The method of claim 1 , wherein the human patient is relapsed/refractory to another tyrosine kinase inhibitor or chemotherapy.

7 . A method for treating a human leukemia patient suffering from both a mutated FLT3 or a constitutively active FLT3 mutant and one or more driver mutations in a NPM1 nuclear transport protein, the method comprising:

first, obtaining a biological sample from a human patient's leukemia;

then assaying the biological sample for expression of a mutated FLT3 receptor or a constitutively active FLT3 receptor, and the presence of one or more driver mutations in a NPM1 nuclear transport protein, and

then administering to the patient a therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof, thereby treating the leukemia which has both a deregulated FLT3 receptor or a constitutively active FTL3 receptor and one or more driver mutations in the NPM1 nuclear transport protein.

8 . The method of claim 7 , wherein the FLT3 mutation is selected from at least one of FLT3-ITD or FLT3-TKD.

9 . The method of claim 7 , wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is administered orally, intravenously, or intraperitoneally.

10 . The method of claim 7 , wherein the method comprises at least one of:

providing the crenolanib or the pharmaceutically acceptable salt thereof is crenolanib besylate, crenolanib phosphate, crenolanib lactate, crenolanib hydrochloride, crenolanib citrate, crenolanib acetate, crenolanib toluenesulphonate, and crenolanib succinate; or

providing at least one of sequentially or concomitantly, with a chemotherapeutic agent to maintain remission, or in a relapsed/refractory leukemia; or

providing as a single agent or in combination with a chemotherapeutic agent for treatment of a human pediatric patient with leukemia; or

providing as a single agent in treatment of patients with the leukemia that is either refractory to, or has relapsed after, prior treatment with a chemotherapeutic agent or a tyrosine kinase inhibitor.

11 . The method of claim 7 , wherein the patient is refractory to at least one other tyrosine kinase inhibitor or a chemotherapy.

12 . A method for treating a human patient suffering from acute myelogenous leukemia (AML) with crenolanib, where the AML is characterized by both a mutated FLT3 or a constitutively active FLT3 mutant and one or more driver mutations in a NPM1 nuclear transport protein, the method comprising:

first, obtaining a biological sample from a human patient's AML;

then, assaying the biological sample for expression of the mutated FLT3 or constitutively active FLT3 mutant, and the presence of one or more driver mutations in a NPM1 nuclear transport protein;

then administering to the patient a therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof, thereby treating the AML which has both the deregulated FLT3 receptor or the constitutively active FLT3 receptor and one or more driver mutations in a NPM1 nuclear transport protein.

13 . The method of claim 12 , wherein the FLT3 receptor mutation is selected from at least one of FLT3-ITD or FLT3-TKD.

Assignments (1)

Continuity (3)

References Cited (180)